Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
30
pubmed:dateCreated
1998-8-21
pubmed:abstractText
A noncovalently bound dimeric form of recombinant human IL-6 interleukin-6 (IL-6D) was shown to be an antagonist for IL-6 activity, in a STAT3 tyrosine phosphorylation assay using HepG2 cells, under conditions where it does not dissociate into monomeric IL-6 (IL-6M). The fluorescence from Trp157, the single tryptophan residue in the primary sequence of IL-6, is altered in IL-6D, where the wavelength maximum is blue-shifted by 3 nm and the emission intensity is reduced by 30%. These data suggest that Trp157 is close to, but not buried by, the dimer interface. Both IL-6D and IL-6M are compact molecules, as determined by sedimentation velocity analysis, and contain essentially identical levels of secondary and tertiary structure, as determined by far- and near-UV CD, respectively. IL-6D and IL-6M show the same susceptibility to limited proteolytic attack, and exhibit identical far-UV CD-monitored urea-denaturation profiles with the midpoint of denaturation occurring at 6.0 +/- 0.1 M urea. However, IL-6D was found to dissociate prior to the complete unfolding of the protein, with a midpoint of dissociation of 3 M urea, suggesting that dissociation and dimerization occur when the protein is in a partially unfolded state. Based on these results, we suggest that IL-6D is a metastable domain-swapped dimer, comprising two monomeric units where identical helices from each protein chain are swapped through the loop regions at the "top" of the protein (i.e., the region of the protein most distal from the N- and C-termini). Such an arrangement would account for the antagonistic activity of IL-6D. In this model, receptor binding site I, which comprises residues in the A/B loop and the C-terminus of the protein, is free to bind the IL-6 receptor. However, site III, which includes Trp157 and residues in the C/D loop and N-terminal end of helix D, and perhaps site II, which comprises residues in the A and C helices, are no longer able to bind the signal transducing component of the IL-6 receptor complex, gp130.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0006-2960
pubmed:author
pubmed:issnType
Print
pubmed:day
28
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
10671-80
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:9692957-Carcinoma, Hepatocellular, pubmed-meshheading:9692957-Chemistry, Physical, pubmed-meshheading:9692957-Circular Dichroism, pubmed-meshheading:9692957-Dimerization, pubmed-meshheading:9692957-Escherichia coli, pubmed-meshheading:9692957-Fluorescence Polarization, pubmed-meshheading:9692957-Humans, pubmed-meshheading:9692957-Interleukin-6, pubmed-meshheading:9692957-Models, Molecular, pubmed-meshheading:9692957-Physicochemical Phenomena, pubmed-meshheading:9692957-Protein Folding, pubmed-meshheading:9692957-Protein Structure, Secondary, pubmed-meshheading:9692957-Protein Structure, Tertiary, pubmed-meshheading:9692957-Recombinant Proteins, pubmed-meshheading:9692957-Signal Transduction, pubmed-meshheading:9692957-Temperature, pubmed-meshheading:9692957-Tumor Cells, Cultured, pubmed-meshheading:9692957-Ultracentrifugation, pubmed-meshheading:9692957-Urea
pubmed:year
1998
pubmed:articleTitle
Physicochemical characterization of an antagonistic human interleukin-6 dimer.
pubmed:affiliation
Joint Protein Structure Laboratory, Ludwig Institute for Cancer Research (Melbourne), Victoria, Australia.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't